Lijuan Wu

Lijuan Wu

Auto-generated profile, based on publicly available information

Lijuan Wu

School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
XHXupang Hu
Xupang Hu
LWLijuan Wu
Lijuan Wu
XLXingyu Liu
Xingyu Liu
YZYi Zhang
Yi Zhang
MXMin Xu
Min Xu
WYWei Yang
Wei Yang
Cerebral ischemia‐reperfusion (I‐R) transiently increased autophagy by producing excessively reactive oxygen species (ROS); on the other hand, activated autophagy would remove ROS‐damaged mitochondria and proteins, which led to cell survival. However, the regulation mechanism of autophagy activity during cerebral I‐R is still unclear. In this study, we found that deficiency of the TRPM2 channel which is a ROS sensor significantly decreased I‐R‐induced neuronal damage. I‐R transiently increased autophagy activity both in vitro and in vivo. More importantly, TRPM2 deficiency decreased I‐R‐induced neurological deficit score and infarct volume. Interestingly, our results indicated that TRPM2 deficiency could further activate AMPK rather than Beclin1 activity, suggesting that TRPM2 inhibits autophagy by regulating the AMPK/mTOR pathway in I‐R. In conclusion, our study reveals that ROS‐activated TRPM2 inhibits autophagy by downregulating the AMPK/mTOR pathway, which results in neuronal death induced by cerebral I‐R, further supporting that TRPM2 might be a potential drug target for cerebral ischemic injury therapy.

24 April 2024 in ACS Pharmacology & Translational Science
Verified
Journal Article
Open access
CZChuanliang Zhang
Chuanliang Zhang
XYXianmin Yang
Xianmin Yang
LWLijuan Wu
Lijuan Wu
FLFei Liu
Fei Liu
KDKehong Dong
Kehong Dong
FSFeng Su
Feng Su
Protein tyrosine phosphatase 1B (PTP1B) and TC-PTP can function in a coordinated manner to regulate diverse biological processes including insulin and leptin signaling, T-cell activation, and tumor antigen presentation, which makes them potential targets for several therapeutic applications. We have previously demonstrated that the lipidated BimBH3 peptide analogues were a new class of promising PTP1B inhibitors with once-weekly antidiabetic potency. Herein, we chemically synthesized two series of BimBH3 analogues via site-specific modification and studied their structure-activity relationship. The screened analogues S2, S6, A2-14, A2-17, A2-20, and A2-21 exhibited an improved PTP1B/TC-PTP dual inhibitory activity and achieved good stability in the plasma of mice and dogs, which indicated long-acting potential. In mouse models of type 2 diabetes mellitus (T2DM), the selected analogues S6, S7, A2-20, and A2-21 with an excellent target activity and plasma stability generated once-weekly therapeutic potency for T2DM at lower dosage (0.5 μmol/kg). In addition, evidence was provided to confirm the cell permeability and targeted enrichment of the BimBH3 analogues. In summary, we report here that site-specific modification and long fatty acid conjugation afforded cell-permeable peptidomimetic analogues of BimBH3 with enhanced stability, in vivo activity, and long-acting pharmacokinetic profile. Our findings could guide the further optimization of BimBH3 analogues and provide a proof-of-concept for PTP1B/TC-PTP targeting as a new therapeutic approach for T2DM, which may facilitate the discovery and development of alternative once-weekly anti-T2DM drug candidates.

5 January 2011 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
JLJingying Li
Jingying Li
HMHuan Ma
Huan Ma
SDShumin Deng
Shumin Deng
LWLijuan Wu
Lijuan Wu
YHYinglin Huang
Yinglin Huang
AZand Gang Zhu
and Gang Zhu